Shares of Oxford Biomedica plc (LON:OXB – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 366.88 ($4.53) and traded as low as GBX 213 ($2.63). Oxford Biomedica shares last traded at GBX 213 ($2.63), with a volume of 156,290 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Liberum Capital dropped their target price on shares of Oxford Biomedica from GBX 350 ($4.32) to GBX 310 ($3.83) and set a “hold” rating for the company in a research report on Tuesday, September 26th.
Oxford Biomedica Stock Performance
Insiders Place Their Bets
In related news, insider Dame Kay Davies bought 1,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The stock was purchased at an average price of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). In other Oxford Biomedica news, insider Roch Doliveux purchased 36,130 shares of Oxford Biomedica stock in a transaction that occurred on Wednesday, September 20th. The stock was acquired at an average price of GBX 274 ($3.38) per share, with a total value of £98,996.20 ($122,202.44). Also, insider Dame Kay Davies acquired 1,000 shares of the company’s stock in a transaction on Tuesday, September 26th. The shares were bought at an average price of GBX 291 ($3.59) per share, for a total transaction of £2,910 ($3,592.15). Corporate insiders own 8.68% of the company’s stock.
About Oxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
- Five stocks we like better than Oxford Biomedica
- There Are Different Types of Stock To Invest In
- Investing in large cap stocks: Diving into big caps
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- The Role Economic Reports Play in a Successful Investment Strategy
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.